These results also provide initial proof-of-concept for a safe and cancer-selective NF-κB-targeting strategy as a novel anticancer therapy which promises to be of profound benefit for patients with multiple myeloma and, potentially, other cancers where NF-κB drives oncogenesis via GADD45β (Fig. 1) (Karin, 2014). Here, NFKB1 is linked to cancer.